Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05642806
PHASE4

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

Sponsor: St. Paul's Sinus Centre

View on ClinicalTrials.gov

Summary

This study aims to analyze the immune profiles of patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) with and without asthma before and after Mepolizumab. A group of participants with CRS without nasal polyps (CRSsNP) with asthma will be included to compare their immune profiles to CRSwNP.

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2023-07-01

Completion Date

2025-06-30

Last Updated

2024-04-17

Healthy Volunteers

No

Interventions

BIOLOGICAL

Mepolizumab

Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

OTHER

Placebo

Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

Locations (1)

St. Pual's Sinus Centre

Vancouver, British Columbia, Canada